CAESAREA, Israel – August 5, 2025 – Epitomee Medical Ltd. (TASE: EPIT) announces a new peer-reviewed publication on the association between early response to treatment with the Epitomee capsule and weight loss.
A new publication in Clinical Obesity underscores the clinical potential of the Epitomee® Capsule, a novel, oral, non-pharmaceutical medical device for weight loss. The study demonstrates that early responders (≥2% weight loss at 8 weeks) treated with Epitomee alongside lifestyle intervention achieved significantly greater weight loss at 24 weeks compared to placebo (9.3% vs. 6.9%, p < 0.0001).
Efficacy was consistent across BMI categories, with weight loss reaching 11.2% in overweight individuals, 9.4% in obesity class I, and 8.9% in class II – all statistically significant. Additionally, 63.6% of Epitomee-treated early responders improved their BMI classification, significantly more than compared to the 43.6% observed in the placebo group.
Adverse events were similar between the Epitomee and placebo groups, supporting the favorable tolerability profile of the capsule.
Link to the full publication in Clinical Obesity: https://doi.org/10.1111/cob.70037
Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center, commented:
“Early response peer-reviewed results showed 9.3% weight loss during 24 weeks when treated with Epitomee-compared to 6.9% with placebo-together with diet and physical activity. These important findings suggest that early response could guide non-pharmacologic treatment decisions by patients and health care professionals, which may result in an enhanced weight loss in adults with overweight or obesity.”
About Epitomee Medical Ltd.: Epitomee Medical Ltd. is a pioneering technology-based health solutions company, committed to advancing innovative therapies. The company is advancing two major fields: weight management and biologic drug delivery. In addition to its flagship weight management solution, Epitomee Medical is developing a cutting-edge platform focused on the oral delivery of biologics. This innovative platform is designed to transport drugs to the absorption site with enhanced bioavailability.
For partnership inquiries and more information about the weight-management capsule, please contact: Mr. Alon Heth
VP Sales and Marketing
alon@epitomeemedical.com
For more information about Epitomee Medical Ltd., please visit Epitomee Medical at: www.epitomeemedical.com
